Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Friday, January 17th. The shares were sold at an average price of $10.72, for a total value of $21,440.00. Following the completion of the transaction, the president now owns 2,907,138 shares of the company’s stock, valued at approximately $31,164,519.36. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Down 2.4 %

NASDAQ GYRE opened at $10.70 on Thursday. Gyre Therapeutics, Inc. has a 52-week low of $8.26 and a 52-week high of $26.37. The company has a fifty day moving average of $11.27 and a 200-day moving average of $12.61.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GYRE. FMR LLC purchased a new stake in Gyre Therapeutics during the third quarter valued at about $47,000. Barclays PLC boosted its holdings in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the period. State Street Corp boosted its holdings in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after acquiring an additional 8,412 shares during the period. Rhumbline Advisers bought a new position in Gyre Therapeutics during the 2nd quarter worth approximately $123,000. Finally, Renaissance Technologies LLC purchased a new position in Gyre Therapeutics in the 2nd quarter worth approximately $166,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.